Zeynep Hülya Gümüş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zeynep Hülya Gümüş has a total of 693 co-authors. Here are the top co-authors by number of shared publications:
- Myvizhi Esai Selvan
Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
27 shared publications - Robert J. Klein
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
26 shared publications - Kenan Onel
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, USA; Department of Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, USA
10 shared publications Baoheng Du
9 shared publicationsJay O. Boyle
9 shared publicationsJennifer M. Bocker
9 shared publications
Latest Publications
- Open Access
The genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort
Clonal hematopoiesis of indeterminate potential (CHIP), the age-associated expansion of blood cell clones carrying acquired driver mutations, remains less well characterized in young adults, across genetic ancestries, and in clinical populations. We analyzed whole-exome sequencing and longitudinal electronic health record (EHR) data from 59,598 adults in the Mount Sinai Million Health Discoveries Program, an urban, multi-ancestry hospital-based cohort that includes substantial representation of African (∼35%) and Admixed American genetic ancestry (∼15%) and young adults aged 18-39 years (∼30%). After sample QC, separate analyses were performed in discovery (n = 28,051) and validation (n = 26,938) cohorts defined by sequencing platform and combined by meta-analysis. CHIP was detected in 8.5% of participants in each cohort and in 4.0% of young adults, with D NMT3A, TET2, ASXL1, and PPM1D the most frequently mutated genes. Prevalence and clone size increased with age across ancestry groups. After adjusting for age, participants of African ancestry had lower CHIP prevalence than those of European ancestry in both cohorts (discovery: OR=0.86, 95% CI = 0.78–0.95, p =0.002; validation: OR=0.84, 95% CI = 0.75–0.93, p =0.001). Participants of Admixed American ancestry showed a similar trend. Higher systemic immune-inflammation index (SII) was associated with CHIP after adjusting for age, sex and ancestry in both cohorts (pooled OR=1.30, 95% CI = 1.15–1.48, p =4.78e-5). Heterozygosity at an HLA class II locus HLA-DPA1 was associated with 7% lower odds of overall CHIP (pooled OR=0.93, 95% CI = 0.87–0.99, p =0.03). Driver-stratified analyses revealed distinct HLA class II nominal association patterns for DNMT3A - and TET2 -mutant CHIP. Particularly, HLA-DQB1 heterozygosity associated with lower odds of TET2 -mutant CHIP (pooled OR=0.84, 95% CI = 0.70–1.00, p =0.05), HLA-DQA1 and HLA-DOB heterozygosity associated with higher odds of DNMT3A -mutant CHIP (pooled OR=1.19, 95% CI = 1.00–1.42, p =0.05; pooled OR=1.12, 95% CI = 1.01–1.25, p =0.03 respectively). Longitudinal EHR analyses revealed CHIP associations with several incident diseases that varied by driver gene and clone size. The broadest pattern of associations involved high-risk CHIP genes and encompassed hematologic malignancies, solid tumors, cardiovascular outcomes, hypertension, and COPD. High-VAF clones were the main drivers of these associations. Among adults aged ≥40 years, phenome-wide analyses identified a Bonferroni-significant association with incident myeloproliferative disease and nominal associations with incident pancytopenia, anemia, cardiomegaly, and chronic renal failure. Young-adult CHIP was nominally associated with incident nodular goiter and esophageal disease. These findings characterize CHIP across adulthood and genetic ancestry and reveal inherited immune variation and systemic inflammation as correlates in a hospital-based population.
Open AccessThe genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort
Clonal hematopoiesis of indeterminate potential (CHIP), the age-associated expansion of blood cell clones carrying acquired driver mutations, remains less well characterized in young adults, across genetic ancestries, and in clinical populations. We analyzed whole-exome sequencing and longitudinal electronic health record (EHR) data from 59,598 adults in the Mount Sinai Million Health Discoveries Program, an urban, multi-ancestry hospital-based cohort that includes substantial representation of African (∼35%) and Admixed American genetic ancestry (∼15%) and young adults aged 18-39 years (∼30%). After sample QC, separate analyses were performed in discovery (n = 28,051) and validation (n = 26,938) cohorts defined by sequencing platform and combined by meta-analysis. CHIP was detected in 8.5% of participants in each cohort and in 4.0% of young adults, with D NMT3A, TET2, ASXL1, and PPM1D the most frequently mutated genes. Prevalence and clone size increased with age across ancestry groups. After adjusting for age, participants of African ancestry had lower CHIP prevalence than those of European ancestry in both cohorts (discovery: OR=0.86, 95% CI = 0.78–0.95, p =0.002; validation: OR=0.84, 95% CI = 0.75–0.93, p =0.001). Participants of Admixed American ancestry showed a similar trend. Higher systemic immune-inflammation index (SII) was associated with CHIP after adjusting for age, sex and ancestry in both cohorts (pooled OR=1.30, 95% CI = 1.15–1.48, p =4.78e-5). Heterozygosity at an HLA class II locus HLA-DPA1 was associated with 7% lower odds of overall CHIP (pooled OR=0.93, 95% CI = 0.87–0.99, p =0.03). Driver-stratified analyses revealed distinct HLA class II nominal association patterns for DNMT3A - and TET2 -mutant CHIP. Particularly, HLA-DQB1 heterozygosity associated with lower odds of TET2 -mutant CHIP (pooled OR=0.84, 95% CI = 0.70–1.00, p =0.05), HLA-DQA1 and HLA-DOB heterozygosity associated with higher odds of DNMT3A -mutant CHIP (pooled OR=1.19, 95% CI = 1.00–1.42, p =0.05; pooled OR=1.12, 95% CI = 1.01–1.25, p =0.03 respectively). Longitudinal EHR analyses revealed CHIP associations with several incident diseases that varied by driver gene and clone size. The broadest pattern of associations involved high-risk CHIP genes and encompassed hematologic malignancies, solid tumors, cardiovascular outcomes, hypertension, and COPD. High-VAF clones were the main drivers of these associations. Among adults aged ≥40 years, phenome-wide analyses identified a Bonferroni-significant association with incident myeloproliferative disease and nominal associations with incident pancytopenia, anemia, cardiomegaly, and chronic renal failure. Young-adult CHIP was nominally associated with incident nodular goiter and esophageal disease. These findings characterize CHIP across adulthood and genetic ancestry and reveal inherited immune variation and systemic inflammation as correlates in a hospital-based population.
- Open Access
Inherited genetic risk factors in young-onset lung cancer
Introduction: Lung cancer is rare before age 45, and its inherited genetic basis remains poorly defined. Methods: We performed whole-genome sequencing in 171 predominantly young-onset lung cancer patients and integrated these data with whole-exome sequencing from six major lung cancer consortia, yielding 9,065 patients. After quality control, analyses focused on 6,545 individuals of European ancestry, the largest ancestral group. We compared the prevalence of rare pathogenic and likely pathogenic (P/LP) germline variants between 186 young-onset (age BRIP1 , ERCC6 , MSH5), and in cilia-related genes, notably GPR161 . At the pathway level, DDR genes were significantly enriched (OR=1.66, p =0.007), with the strongest signal in the Fanconi Anemia pathway and among females (OR=1.96, p =0.01). Enrichment was also observed in inborn errors of immunity pathways, with strongest signals in antibody deficiency and the complement system genes. Young-onset patients additionally exhibited higher lung cancer PRS. Conclusion: Young-onset lung cancer exhibits a distinct germline genetic architecture, characterized by enrichment of rare P/LP variants in DDR, cilia-related, and immune pathways, and an elevated lung cancer PRS. These findings support a greater role for inherited susceptibility in early-onset disease and have implications for risk stratification, earlier screening, and precision prevention.
Open AccessInherited genetic risk factors in young-onset lung cancer
Introduction: Lung cancer is rare before age 45, and its inherited genetic basis remains poorly defined. Methods: We performed whole-genome sequencing in 171 predominantly young-onset lung cancer patients and integrated these data with whole-exome sequencing from six major lung cancer consortia, yielding 9,065 patients. After quality control, analyses focused on 6,545 individuals of European ancestry, the largest ancestral group. We compared the prevalence of rare pathogenic and likely pathogenic (P/LP) germline variants between 186 young-onset (age BRIP1 , ERCC6 , MSH5), and in cilia-related genes, notably GPR161 . At the pathway level, DDR genes were significantly enriched (OR=1.66, p =0.007), with the strongest signal in the Fanconi Anemia pathway and among females (OR=1.96, p =0.01). Enrichment was also observed in inborn errors of immunity pathways, with strongest signals in antibody deficiency and the complement system genes. Young-onset patients additionally exhibited higher lung cancer PRS. Conclusion: Young-onset lung cancer exhibits a distinct germline genetic architecture, characterized by enrichment of rare P/LP variants in DDR, cilia-related, and immune pathways, and an elevated lung cancer PRS. These findings support a greater role for inherited susceptibility in early-onset disease and have implications for risk stratification, earlier screening, and precision prevention.
- Open Access
- 9 February 2026
ClusterChirp: A GPU-accelerated Web Server for Natural Language–Guided Interactive Visualization and Analysis of Large Omics Data
Tabular datasets are commonly visualized as heatmaps, where data values are represented as color intensities in a matrix to reveal patterns and correlations. However, modern omics technologies increasingly generate matrices so large that existing visual exploration tools require downsampling or filtering, risking loss of biologically important patterns. Additional barriers arise from tools that require command-line expertise, or fragmented workflows for downstream biological interpretation. We present ClusterChirp, a web-based platform for real-time, interactive exploration of large-scale data matrices enabled by GPU-accelerated rendering and parallelized hierarchical clustering using multiple CPU cores. Built on deck.gl and multi-threaded clustering algorithms, ClusterChirp supports on-the-fly clustering, multi-metric sorting, feature search, and adjustable visualization parameters for interactive explorations. Uniquely, a natural language interface powered by a Large Language Model helps users perform complex operations and build reproducible workflows from conversational commands. Furthermore, users can select clusters to explore interactive within-cluster correlation networks in 2D or 3D, or perform functional enrichment through biological knowledge bases. Developed with iterative user feedback and adhering to FAIR4S principles, ClusterChirp empowers researchers to extract insights from high-dimensional omics data with unprecedented ease and speed. This website is freely available at clusterchirp.mssm.edu, with no login required.
- 9 February 2026
Open AccessClusterChirp: A GPU-accelerated Web Server for Natural Language–Guided Interactive Visualization and Analysis of Large Omics Data
Tabular datasets are commonly visualized as heatmaps, where data values are represented as color intensities in a matrix to reveal patterns and correlations. However, modern omics technologies increasingly generate matrices so large that existing visual exploration tools require downsampling or filtering, risking loss of biologically important patterns. Additional barriers arise from tools that require command-line expertise, or fragmented workflows for downstream biological interpretation. We present ClusterChirp, a web-based platform for real-time, interactive exploration of large-scale data matrices enabled by GPU-accelerated rendering and parallelized hierarchical clustering using multiple CPU cores. Built on deck.gl and multi-threaded clustering algorithms, ClusterChirp supports on-the-fly clustering, multi-metric sorting, feature search, and adjustable visualization parameters for interactive explorations. Uniquely, a natural language interface powered by a Large Language Model helps users perform complex operations and build reproducible workflows from conversational commands. Furthermore, users can select clusters to explore interactive within-cluster correlation networks in 2D or 3D, or perform functional enrichment through biological knowledge bases. Developed with iterative user feedback and adhering to FAIR4S principles, ClusterChirp empowers researchers to extract insights from high-dimensional omics data with unprecedented ease and speed. This website is freely available at clusterchirp.mssm.edu, with no login required.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
Supplementary Figure from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
Supplementary Figure from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
Background:A previous genome-wide association study identified several loci with genetic variants associated with prostate cancer survival time in two cohorts from Sweden. Whether these variants have an effect in other populations or if their effect is homogenous across the course of disease is unknown.Methods:These variants were genotyped in a cohort of 1,298 patients. Samples were linked with age, PSA level, Gleason score, cancer stage at surgery, and times from surgery to biochemical recurrence to death from prostate cancer. SNPs rs2702185 and rs73055188 were tested for association with prostate cancer–specific survival time using a multivariate Cox proportional hazard model. SNP rs2702185 was further tested for association with time to biochemical recurrence and time from biochemical recurrence to death with a multi-state model.Results:SNP rs2702185 at SMG7 was associated with prostate cancer–specific survival time, specifically the time from biochemical recurrence to prostate cancer death (HR, 2.5; 95% confidence interval, 1.4–4.5; P = 0.0014). Nine variants were in linkage disequilibrium (LD) with rs2702185; one, rs10737246, was found to be most likely to be functional based on LD patterns and overlap with open chromatin. Patterns of open chromatin and correlation with gene expression suggest that this SNP may affect expression of SMG7 in T cells.Conclusions: The SNP rs2702185 at the SMG7 locus is associated with time from biochemical recurrence to prostate cancer death, and its LD partner rs10737246 is predicted to be functional.Impact:These results suggest that future association studies of prostate cancer survival should consider various intervals over the course of disease.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
Background:A previous genome-wide association study identified several loci with genetic variants associated with prostate cancer survival time in two cohorts from Sweden. Whether these variants have an effect in other populations or if their effect is homogenous across the course of disease is unknown.Methods:These variants were genotyped in a cohort of 1,298 patients. Samples were linked with age, PSA level, Gleason score, cancer stage at surgery, and times from surgery to biochemical recurrence to death from prostate cancer. SNPs rs2702185 and rs73055188 were tested for association with prostate cancer–specific survival time using a multivariate Cox proportional hazard model. SNP rs2702185 was further tested for association with time to biochemical recurrence and time from biochemical recurrence to death with a multi-state model.Results:SNP rs2702185 at SMG7 was associated with prostate cancer–specific survival time, specifically the time from biochemical recurrence to prostate cancer death (HR, 2.5; 95% confidence interval, 1.4–4.5; P = 0.0014). Nine variants were in linkage disequilibrium (LD) with rs2702185; one, rs10737246, was found to be most likely to be functional based on LD patterns and overlap with open chromatin. Patterns of open chromatin and correlation with gene expression suggest that this SNP may affect expression of SMG7 in T cells.Conclusions: The SNP rs2702185 at the SMG7 locus is associated with time from biochemical recurrence to prostate cancer death, and its LD partner rs10737246 is predicted to be functional.Impact:These results suggest that future association studies of prostate cancer survival should consider various intervals over the course of disease.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
Supplementary Data from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
Supplementary Data from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 29 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1873-1877
Distinct Characteristics of Lymphoid and Myeloid Clonal Hematopoiesis in World Trade Center First Responders
- 29 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1873-1877
Distinct Characteristics of Lymphoid and Myeloid Clonal Hematopoiesis in World Trade Center First Responders